Synonym: (+)-1-(3S,4R)-[3-(4-Phenylbenzyl)-4-hydroxychroman-7-yl]cyclopentane carboxylic acid; 1-[(3S,4R)-3-([1,1′-Biphenyl]-4-ylmethyl)-3,4-dihydro-4-hydroxy-2H-1-benzopyran-7-yl]-cyclopentanecarboxylic acid; CP-105696; CP105696
CAS Number: 158081-99-3
Empirical Formula (Hill Notation): C28H28O4
Molecular Weight: 428.52
MDL Number: MFCD00934881
Linear Formula: C28H28O4
Product Type: Chemical
This picture is provided solely for illustration purposes, it may have been created or edited with AI. Optical properties of the actual product may deviate. Relevant product information is printed on labeled products and other accompanying or available information material.
This image depicts PZ0363-5MG.
| assay |
≥98% (HPLC) |
| color |
white to beige |
| form |
powder |
| InChI key |
KMNLXCBYBKHKSK-BKMJKUGQSA-N |
| SMILES string |
OC(C1(CCCC1)C(C=C2)=CC3=C2[C@H](O)[C@@H](CC4=CC=C(C5=CC=CC=C5)C=C4)CO3)=O |
| storage temp. |
room temp |
| Application: |
CP-105,696 has been used as a leukotriene B4 receptor (LTB4R) antagonist to study the influence of the LTB4 pathway in the pathogenesis of acute itch flares in irritant calcipotriol (MC903)+ model allergen ovalbumin (OVA) sensitized murine model of atopic dermatitis (AD)-like disease. |
| Biochem/physiol Actions: |
CP-105,696 is an orally active, potent and selective leukotriene B4 receptor (LTB4R) antagonist (IC50 against [3H]LTB4 = 5.6 nM for binding human neutrophils; IC50 = 9.7 nM & 30.3 nM, respectively using guinea pig spleen or mouse membranes) that targets LTB4R high- and low-affinity binding sites in a LTB4 non-competitive and competitive manner, respectively. CP-105,696 inhibits 5 nM LTB4-induced human neutrophils chemotaxis and CDllb upregualtion (IC50 = 5.2 nM and 430 nM, respectively) without inhibiting cyclooxygenase activity or affecting chemotaxis induced by C5a, PAF, IL-8. Oral administration is efficacious against intradermal LTB4 (100 ng/mouse), but not IL-1, injection-induced neutrophil accumulation in mice and guinea pigs (ED50 = 4.2 and 0.26 mgkg, respectively). CP-105,696 in vivo efficacy is also demonstrated in other animal models, including collagen-induced arthritis (CIA; 0.3-10 mg/kg in mice), allergic encephalomyelitis (ED50= 8.6 mg/kg; mice), and asthma (10-30 mg/kg; primate). |
| Purity |
≥98% (HPLC) |
| Storage Temp. |
room temp |
| UNSPSC |
51111800 |